生物制剂治疗系统性红斑狼疮的随机安慰剂对照3期试验中减少激素用量的系统评价与Meta分析
该系统评价与Meta分析检索了截至2017年4月18日的Medline、EMBASE、CINAHL、SCOPUS、Cochrane图书馆及clinicaltrials.gov,纳入28项研究(9项SLE、5项狼疮肾炎、14项3期试验事后分析),评估生物制剂在3期随机安慰剂对照试验中的减少激素用量效应。除贝利尤单抗外,其他生物制剂3期试验均未达到主要终点。
要点
- 仅贝利尤单抗的3项试验达到主要终点。
- 三项研究因严重副作用提前终止。
核心结论
- 除贝利尤单抗外,SLE生物制剂3期试验均未达到主要终点。
- 这些药物显著的减少激素用量效应提示未来试验可能需要将激素剂量纳入复合主要终点。
研究设计与样本
- 系统评价与Meta分析,检索Medline、EMBASE、CINAHL、SCOPUS、Cochrane图书馆及clinicaltrials.gov。
- 纳入近十年(截至2017年4月18日)发表的英文成人研究。
- 共纳入28项研究:9项在SLE、5项在狼疮肾炎、14项为SLE 3期试验的事后分析。
- 对利妥昔单抗、贝利尤单抗、tabalumab和epratuzumab试验中共同的激素减量终点进行随机效应Meta分析。
主要发现
- 所有试验药物均靶向B细胞(利妥昔单抗、贝利尤单抗、tabalumab、epratuzumab、阿塞西普、奥瑞珠单抗),除外阿贝莫司钠和阿巴西普。
- 仅贝利尤单抗的三项试验达到主要终点,其他研究常可见次要终点获益和血清学活动度降低。
- 治疗总体耐受良好,但三项研究因严重副作用提前终止。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To systematically review, and conduct a meta-analysis of steroid-sparing effect in, phase 3 randomized, placebo-controlled trials of biologic therapies for systemic lupus erythematosus (SLE). METHODS: Studies were identified by searching Medline (via Pubmed), EMBASE, CINAHL and SCOPUS databases, the Cochrane library, and clinicaltrials.gov. Adult human studies published in English in the last ten years (until 18/04/2017) were included. A random-effects meta-analysis comparing a common corticosteroid-reduction endpoint in the trials of rituximab, belimumab, tabalumab and epratuzumab in SLE, was conducted. RESULTS: Twenty-eight studies were identified; nine were conducted in SLE, five in lupus nephritis and the remaining 14 were post hoc analyses of phase 3 trials in SLE. All therapies trialed targeted B-cells (rituximab (anti-CD20 monoclonal antibody (mAb)), belimumab (anti-BAFF mAb), tabalumab (anti-BAFF mAb), epratuzumab (anti-CD22 mAb), atacicept (TACI-Ig), ocrelizumab (anti-CD20 mAb)), except for abetimus sodium and abatacept (CTLA4-Ig). Only the three trials of belimumab met their primary endpoints, although benefit in secondary endpoints and reduction in serological activity was often seen in the other studies. Meta-analysis showed that most therapies (belimumab, tabalumab, and epratuzumab) had a steroid-sparing effect, compared to placebo (pooled RR 1.36 (1.19, 1.56), I2 = 0, p < 0.67). Therapies were generally well tolerated; however, three studies were terminated prematurely due to serious side effects. CONCLUSIONS: With the exception of belimumab, none of the phase 3 trials of biologic therapy in SLE have met their primary endpoint. However, the significant steroid-sparing effect of these agents suggests that future trials may need to include steroid dose in a composite primary endpoint.
引用
- Oon S, Huq M, Godfrey T, et al. Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus. Semin Arthritis Rheum. 2018. PMID: 29426575. doi:10.1016/j.semarthrit.2018.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。